vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and Xometry, Inc. (XMTR). Click either name above to swap in a different company.
COLLEGIUM PHARMACEUTICAL, INC is the larger business by last-quarter revenue ($205.4M vs $192.4M, roughly 1.1× Xometry, Inc.). COLLEGIUM PHARMACEUTICAL, INC runs the higher net margin — 8.3% vs -4.5%, a 12.7% gap on every dollar of revenue. On growth, Xometry, Inc. posted the faster year-over-year revenue change (29.5% vs 12.9%). COLLEGIUM PHARMACEUTICAL, INC produced more free cash flow last quarter ($122.4M vs $-5.9M). Over the past eight quarters, Xometry, Inc.'s revenue compounded faster (25.2% CAGR vs 19.1%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
Xometry is an online marketplace for sourcing on-demand manufactured parts for prototyping and large-scale production.
COLL vs XMTR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $192.4M |
| Net Profit | $17.0M | $-8.6M |
| Gross Margin | 62.5% | 39.1% |
| Operating Margin | 29.6% | -4.6% |
| Net Margin | 8.3% | -4.5% |
| Revenue YoY | 12.9% | 29.5% |
| Net Profit YoY | 35.3% | 12.7% |
| EPS (diluted) | $0.48 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $205.4M | $192.4M | ||
| Q3 25 | $209.4M | $180.7M | ||
| Q2 25 | $188.0M | $162.5M | ||
| Q1 25 | $177.8M | $151.0M | ||
| Q4 24 | $181.9M | $148.5M | ||
| Q3 24 | $159.3M | $141.7M | ||
| Q2 24 | $145.3M | $132.6M | ||
| Q1 24 | $144.9M | $122.7M |
| Q4 25 | $17.0M | $-8.6M | ||
| Q3 25 | $31.5M | $-11.6M | ||
| Q2 25 | $12.0M | $-26.4M | ||
| Q1 25 | $2.4M | $-15.1M | ||
| Q4 24 | $12.5M | $-9.9M | ||
| Q3 24 | $9.3M | $-10.2M | ||
| Q2 24 | $19.6M | $-13.7M | ||
| Q1 24 | $27.7M | $-16.6M |
| Q4 25 | 62.5% | 39.1% | ||
| Q3 25 | 61.7% | 39.9% | ||
| Q2 25 | 57.7% | 40.1% | ||
| Q1 25 | 54.8% | 37.3% | ||
| Q4 24 | 54.0% | 39.7% | ||
| Q3 24 | 60.8% | 39.4% | ||
| Q2 24 | 62.5% | 39.9% | ||
| Q1 24 | 63.1% | 39.0% |
| Q4 25 | 29.6% | -4.6% | ||
| Q3 25 | 29.7% | -6.1% | ||
| Q2 25 | 18.7% | -6.3% | ||
| Q1 25 | 12.2% | -10.2% | ||
| Q4 24 | 20.9% | -7.8% | ||
| Q3 24 | 21.9% | -8.1% | ||
| Q2 24 | 32.7% | -11.5% | ||
| Q1 24 | 34.1% | -14.6% |
| Q4 25 | 8.3% | -4.5% | ||
| Q3 25 | 15.0% | -6.4% | ||
| Q2 25 | 6.4% | -16.3% | ||
| Q1 25 | 1.4% | -10.0% | ||
| Q4 24 | 6.9% | -6.7% | ||
| Q3 24 | 5.9% | -7.2% | ||
| Q2 24 | 13.5% | -10.3% | ||
| Q1 24 | 19.1% | -13.5% |
| Q4 25 | $0.48 | — | ||
| Q3 25 | $0.84 | — | ||
| Q2 25 | $0.34 | — | ||
| Q1 25 | $0.07 | — | ||
| Q4 24 | $0.36 | — | ||
| Q3 24 | $0.27 | — | ||
| Q2 24 | $0.52 | — | ||
| Q1 24 | $0.71 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $219.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $275.6M |
| Total Assets | $1.7B | $703.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $386.7M | $219.1M | ||
| Q3 25 | $285.9M | $224.5M | ||
| Q2 25 | $222.2M | $225.8M | ||
| Q1 25 | $197.8M | $231.4M | ||
| Q4 24 | $162.8M | $239.8M | ||
| Q3 24 | $120.0M | $234.0M | ||
| Q2 24 | $271.6M | $240.9M | ||
| Q1 24 | $318.0M | $253.8M |
| Q4 25 | $301.7M | $275.6M | ||
| Q3 25 | $274.8M | $272.0M | ||
| Q2 25 | $232.2M | $270.4M | ||
| Q1 25 | $234.4M | $309.9M | ||
| Q4 24 | $228.8M | $314.5M | ||
| Q3 24 | $234.3M | $315.2M | ||
| Q2 24 | $216.6M | $315.8M | ||
| Q1 24 | $222.2M | $320.4M |
| Q4 25 | $1.7B | $703.7M | ||
| Q3 25 | $1.6B | $698.9M | ||
| Q2 25 | $1.6B | $687.0M | ||
| Q1 25 | $1.6B | $690.1M | ||
| Q4 24 | $1.7B | $680.1M | ||
| Q3 24 | $1.6B | $678.2M | ||
| Q2 24 | $1.1B | $678.6M | ||
| Q1 24 | $1.1B | $692.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | $4.4M |
| Free Cash FlowOCF − Capex | $122.4M | $-5.9M |
| FCF MarginFCF / Revenue | 59.6% | -3.0% |
| Capex IntensityCapex / Revenue | 0.3% | 5.3% |
| Cash ConversionOCF / Net Profit | 7.25× | — |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | $-24.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $123.0M | $4.4M | ||
| Q3 25 | $78.4M | $5.8M | ||
| Q2 25 | $72.4M | $-427.0K | ||
| Q1 25 | $55.4M | $-3.7M | ||
| Q4 24 | $84.6M | $9.1M | ||
| Q3 24 | $-9.0M | $-3.6M | ||
| Q2 24 | $67.4M | $-9.1M | ||
| Q1 24 | $61.9M | $-11.7M |
| Q4 25 | $122.4M | $-5.9M | ||
| Q3 25 | $78.3M | $-1.7M | ||
| Q2 25 | $72.4M | $-7.4M | ||
| Q1 25 | $54.6M | $-9.2M | ||
| Q4 24 | $84.1M | $4.5M | ||
| Q3 24 | $-9.2M | $-8.4M | ||
| Q2 24 | $67.1M | $-13.5M | ||
| Q1 24 | $61.4M | $-16.1M |
| Q4 25 | 59.6% | -3.0% | ||
| Q3 25 | 37.4% | -0.9% | ||
| Q2 25 | 38.5% | -4.5% | ||
| Q1 25 | 30.7% | -6.1% | ||
| Q4 24 | 46.2% | 3.1% | ||
| Q3 24 | -5.8% | -6.0% | ||
| Q2 24 | 46.2% | -10.2% | ||
| Q1 24 | 42.3% | -13.1% |
| Q4 25 | 0.3% | 5.3% | ||
| Q3 25 | 0.1% | 4.1% | ||
| Q2 25 | 0.0% | 4.3% | ||
| Q1 25 | 0.4% | 3.6% | ||
| Q4 24 | 0.3% | 3.1% | ||
| Q3 24 | 0.2% | 3.4% | ||
| Q2 24 | 0.2% | 3.3% | ||
| Q1 24 | 0.4% | 3.5% |
| Q4 25 | 7.25× | — | ||
| Q3 25 | 2.49× | — | ||
| Q2 25 | 6.05× | — | ||
| Q1 25 | 22.92× | — | ||
| Q4 24 | 6.75× | — | ||
| Q3 24 | -0.96× | — | ||
| Q2 24 | 3.44× | — | ||
| Q1 24 | 2.23× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COLL
Segment breakdown not available.
XMTR
| US | $159.1M | 83% |
| Non Us | $33.3M | 17% |
